Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eledon Pharmaceuticals, Inc. on September 11, 2023. The report discloses the appointment of a new director to the Board of Directors, effective October 1, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change is the appointment of James Robinson to the Board of Directors. Key details include:
- Role: Independent Director, expected to serve on the Audit Committee and chair the Compensation Committee.
- Cash Compensation: Annual retainers totaling $68,250 ($42,000 for Board service, $15,750 for Compensation Committee chair, and $10,500 for Audit Committee membership).
- Equity Grant: Option to purchase 150,437 shares of Common Stock at the market price on the grant date (October 2, 2023).
- Vesting Schedule: 50% of shares vest on the first anniversary of the grant date; the remaining 50% vest on the second anniversary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. A noted contingency is the execution of a standard indemnification agreement, under which Eledon may be required to indemnify Mr. Robinson for expenses, judgments, fines, and settlement amounts arising from his service as a director.
Investor Verification Checklist
- Verify the market share price on October 2, 2023, to determine the exercise price of the 150,437 stock options granted.
- Confirm the total annual cash compensation obligation of $68,250 for the new director.
- Review the standard indemnification agreement (Exhibit 10.1) for specific liability caps or exclusions.
- Check subsequent filings to confirm Mr. Robinson's actual start date and committee assignments.